/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Our focus is primarily on developing innovative therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS.
$1.77
+$0.10 (+5.99%)
EOD Sep 18, 2026
Negative free cash flow of -$9M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$58M
▼ -331.7% YoY
Op. Margin
—
ROIC
-21.61%
▲ +6309.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▼ -1124.6% YoY
Op. Cash Flow (TTM)
-$13M
▼ -1116.8% YoY
Net Debt
$5M
Cash & Equiv.
$278K
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.